We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Optimization Models Improve Radiation Therapy for Cancer Patients

By HospiMedica International staff writers
Posted on 02 Nov 2011
Engineering researchers have developed mathematical optimization models that will make radiation treatment plans safer and more efficient than conventional plans.

Conventional radiation therapy uses a single, cumulative treatment plan that disregards changes in tumor geometry and biology over time. More...
However, recent technologic developments have made it possible to capture these changes throughout the course of treatment.

Working with geometric and biologic data gathered from the most advanced technology used to capture tumor changes, the University of Arkansas (Fayetteville, USA) researchers achieve optimization in terms of delivering the maximum dose of energy to the tumor without undue risk to surrounding healthy tissues. By integrating the most recent data about tumor geometry and biology, the researchers’ models will help optimize radiation treatment on a per-session and cumulative basis.

“This is one of the first efforts to develop a method of radiation therapy optimization that uses biological information while maintaining both cumulative and per-fraction, or per-session, dose constraints,” said Dr. Behlul Saka, who recently completed his doctorate in industrial engineering. “Our optimization models may be used to generate treatment plans based on tumor biology prior to treatment, but also may react to changing tumor biology throughout treatment.”

More than one million people in the United States alone are diagnosed with cancer yearly, and more than half of these patients receive radiation therapy at some point during treatment. This type of therapy destroys cancer cells or slows their rate of growth by applying high-energy rays to tumors. Traditional radiation therapy involves shooting radiation from different beam angles with a linear accelerator that rotates around the patient. The variety of beam angles limits radiation exposure and thus spare healthy tissues exposed from particular angles while concentrating their combined effect on the tumor. Care is usually taken to ensure homogeneous distributions of radiation across the tumor.

Intensity-modulated radiation therapy (IMRT) addresses the limitations of conventional radiation therapy by delivering small parts of rays, called beamlets, directly to specific sections or specific points on a tumor while also sparing healthy tissue. To clarify, with IMRT, the radiation dose conforms more precisely to the three-dimensional (3D) shape of the tumor.

Dr. Saka’s research adds to the advantages of IMRT by developing optimized treatment plans in response to changes in tumor geometry measured against cumulative and per-session doses. To build the models, he relied on anonymous, archived patient data. Dr. Saka tested the models on two simulated cases of lung cancer. These cases demonstrated clinically significant improvements in tumor response over time. On a different simulated test case, by comparing tumor hypoxia information, the models demonstrated considerable improvements in controlling a tumor. These gains in tumor control and average doses were significant throughout treatment. The models also displayed the volatility of tumor control in relation to emerging alterations in tumor hypoxia values.

“This work suggests that a homogeneous approach to dose distributions across the tumor can be greatly improved upon,” Dr. Saka said. “Nonhomogeneous distributions that [are] varying doses according biological responses of the tumor apparently can be much more effective. Of course, clinical trials will be required to confirm these simulation findings.”

Dr. Saka continues his research on improved cancer treatment planning as a research scientist at Elekta, AB (Stockholm, Sweden), a healthcare company that develops clinical solutions for treating cancer and brain disorders. His work at the University of Arkansas was completed under the direction of Ron Rardin, professor also director of the Center for Innovation in Healthcare Logistics at the University of Arkansas. Prof. Rardin and his students have been working on radiation planning optimization for more than a decade. “I believe Behlul’s work points the way to much more refined treatment planning, by exploiting more of the information available as the tumor changes through 25 to 50 daily treatment sessions,” Prof. Rardin said. Prof. Rardin is also director of the Center for Innovation in Healthcare Logistics at the University of Arkansas.

Related Links:

University of Arkansas
Elekta





Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.